Study to the effect of teriparatide formulation Forteo versus Teribon on bisphosphonate-related osteonecrosis of the jaw in osteoporosis patients.

Study to the effect of teriparatide formulation Forteo versus Teribon on bisphosphonate-related osteonecrosis of the jaw in osteoporosis patients. - Comparative study of teriparatide formulation Forteo versus Teribon on bisphosphonate-related osteonecrosis of the jaw

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009132

Enrollment

Registered

2012-10-17

Start date

2012-08-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bisphosphonate-related osteonecrosis of the jaw

Interventions

Forteo (teriparatide formulation) Teribone (teriparatide formulation)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1)The patients who require continued treatment for osteoporosis. 2)female patients with bisphosphonate-related osteonecrosis of the jaw. 3)the stage of bisphosphonate-related osteonecrosis of the jaw is 2 or more. 4)outpatients. 5)Signed informed consent forms are obtained by the patients.

Exclusion criteria

Exclusion criteria: 1) Hypercalcemic disorders 2)Potential risk of osteocarcoma (1)Patients with Paget's disease of bone (2)Unexplained elevations of alkaline phosphatase. (3)Young adult patients with open epiphyses. (4)Patients with prior external beam or implant radiation involving the skeleton. 3)Patients with bone metastases, history of skeletal malignancies. 4)Metabolic bone diseases other than osteoporosis. 5)Pregnancy or women with suspected pregnancy. 6)Patients with hypersensitivity to teriparatide or to any of its excipients. 7)Serious cardiac disease, serious hepatic disorder , renal disease. 8)Use of active vitamin D3 or Digoxin. 9)The patients who could not be provided with informed consent. 10)Unsuitability for the trial based on clinical judgement.

Design outcomes

Primary

Measure	Time frame
pain bone formation	—

Countries

Japan

Contacts

Public ContactYumiko OHBAYASHI

Kagawa University Department of Oral and Maxillofacial Surgery, Faculty of Medicine

yumiko@med.kagawa-u.ac.jp087-891-2227

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026